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Abstract
Bats harbor many viruses, which are periodically transmitted to humans resulting in outbreaks of disease (e.g., Ebola, SARS-
CoV). Recently, influenza virus-like sequences were identified in bats; however, the viruses could not be cultured. This
discovery aroused great interest in understanding the evolutionary history and pandemic potential of bat-influenza. Using
synthetic genomics, we were unable to rescue the wild type bat virus, but could rescue a modified bat-influenza virus that
had the HA and NA coding regions replaced with those of A/PR/8/1934 (H1N1). This modified bat-influenza virus replicated
efficiently in vitro and in mice, resulting in severe disease. Additional studies using a bat-influenza virus that had the HA and
NA of A/swine/Texas/4199-2/1998 (H3N2) showed that the PR8 HA and NA contributed to the pathogenicity in mice. Unlike
other influenza viruses, engineering truncations hypothesized to reduce interferon antagonism into the NS1 protein didn’t
attenuate bat-influenza. In contrast, substitution of a putative virulence mutation from the bat-influenza PB2 significantly
attenuated the virus in mice and introduction of a putative virulence mutation increased its pathogenicity. Mini-genome
replication studies and virus reassortment experiments demonstrated that bat-influenza has very limited genetic and
protein compatibility with Type A or Type B influenza viruses, yet it readily reassorts with another divergent bat-influenza
virus, suggesting that the bat-influenza lineage may represent a new Genus/Species within the Orthomyxoviridae family.
Collectively, our data indicate that the bat-influenza viruses recently identified are authentic viruses that pose little, if any,
pandemic threat to humans; however, they provide new insights into the evolution and basic biology of influenza viruses.
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Introduction
Bats are present throughout most of the world and account for
more than a fifth of mammalian species. They are natural
reservoirs of some of the most deadly zoonotic viruses, including
rabies virus, Ebola virus, Henipaviruses, and SARS coronavirus
[1,2]. Recently, nucleic acids obtained from bat samples indicated
bats may be a reservoir of a new group of influenza viruses (bat-
influenza) that are phylogenetically very distantly related to other
influenza viruses [3,4]. Type A, B, and C influenza viruses belong
to the Orthomyxoviridae family and their genomes are composed
of 7–8 negative sense RNA segments (vRNAs). While influenza B
(IBV) and C viruses mainly infect human hosts, influenza A virus
(IAV) has a broad host range; including humans, marine mammals,
horses, pigs, waterfowl, and poultry. New subtypes of IAV, which
have novel hemagglutinin (HA) and/or neuraminidase (NA) surface
glycoproteins, are introduced into the human population by
zoonosis and this periodically leads to devastating pandemics. Past
pandemics include the ‘‘Spanish flu’’ (H1N1) in 1918, ‘‘Asian flu’’
(H2N2) in 1957, ‘‘Hong Kong flu’’ (H3N2) in 1968, ‘‘Russian flu’’
(H1N1) in 1977, and the recent ‘‘swine origin’’ flu (pH1N1) in 2009.
Pandemic viruses are often reassortant viruses composed of vRNAs
that are derived from multiple IAV lineages that previously
circulated in swine and/or avian reservoirs (e.g., 1957 avian-human
reassortant, 1968 avian-human reassortant, and 2009 avian-swine-
human reassortant). The discovery of putative bat-influenza viruses
expands the known host species reservoirs that may serve as a source
of novel viruses, which is a major concern for public and animal
health [4,5].
Infectious bat-influenza viruses couldn’t be isolated [3,4] and
although several structural and biochemical characterization
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studies have been conducted with the putative bat-influenza HA,
NA, and part of PA, none of the vRNAs have been shown to be
functional in a replicative virus [3,4,6–10]. This has led to
questions such as: (1) are the putative bat-influenza vRNA
sequences identified derived from infectious viruses or are they
merely nucleic acid relics harbored in bats [5], (2) are the vRNA
segments sequenced from a single bat-influenza virus or are they
from multiple potentially incompatible viruses, and (3) were the
sequences of the complete gene segments, which is a significant
technical challenge, determined accurately. The inability to
culture infectious viruses is the major hurdle to confirm the
existence of these novel influenza viruses, and to answer important
questions, such as pathogenicity in animal models, ability to
reassort with other influenza viruses, and their potential risk to
public health [5,11]. The goals of this study were to synthesize the
complete viral genome, characterize the bat-influenza virus using
non-infectious approaches, then generate a replicative virus, and
use it as a model to better understand bat-influenza viruses.
Results
Synthetic genomics generated bat-influenza virus-like
particles but they were not infectious in many host cell
substrates
Lack of infectious particles in the original bat specimens is a
potential factor in the inability to isolate/culture bat-influenza
using multiple host cell substrates [3]. Based on digital sequence
information published by Tong et al. [3], we synthesized the
complete genome of A/little yellow-shouldered bat/Guatemala/
164/2009 (H17N10) (Fig. S1) and cloned it into reverse genetics
plasmids to rescue this putative bat-influenza virus (Bat09).
Thousands of spherical influenza-like particles budded into the
supernatants of human cells (293T) transfected with the Bat09
reverse genetics plasmids (Fig. 1A). The supernatants were
inoculated into embryonated chicken eggs and cell lines derived
from many species (canine (MDCK), mink (Mv1-Lu), swine (ST),
African green monkey (Vero), human (A549, Calu-3), and free-
tailed bat (Tadarida brasiliensis, Tb1Lu); however, none of the
host cell substrates tested supported productive virus infection
(determined by serial passage and subsequent real-time RT-PCR).
Previous biochemical and structural studies with purified
proteins of Bat09 hemagglutinin (HA) and neuraminidase (NA)
Figure 1. Generation of viruses relevant to Bat09. (A) EM picture
of Bat09 (left), Bat09:mH1mN1 (middle), and PR8 (right). (B) Viral titers in
transfection supernatants of Bat09 and PR8-HA/NA reassortants, and
Bat09:mH1mN1. Each bar represents an independent rescue experi-
ment. (C) The mH1 contains PR8-HA coding region and Bat09-HA
packaging region (start codon removed). The mN1 was constructed
using the same strategy. (See Fig. S2A for details.) (D) Bat09:mH1mN1
and PR8 replication kinetics in MDCK cells. (E) Peak titers of the viruses
in embryonated chicken eggs. *, P,0.05, compared to PR8.
doi:10.1371/journal.ppat.1004420.g001
Author Summary
The identification of influenza virus-like sequences in two
different bat species has generated great interest in
understanding their biology, ability to mix with other
influenza viruses, and their public health threat. Unfortu-
nately, bat-influenza viruses couldn’t be cultured from the
samples containing the influenza-like nucleic acids. We
used synthetic genomics strategies to create wild type bat-
influenza, or bat-influenza modified by substituting the
surface glycoproteins with those of model influenza A
viruses. Although influenza virus-like particles were pro-
duced from both synthetic genomes, only the modified
bat-influenza viruses could be cultured. The modified bat-
influenza viruses replicated efficiently in vitro and an H1N1
modified version caused severe disease in mice. Collec-
tively our data show: (1) the two bat-flu genomes
identified in other studies are replication competent,
suggesting that host cell specificity is the major limitation
for propagation of bat-influenza, (2) bat-influenza NS1
antagonizes host interferon response more efficiently than
that of a model influenza A virus, (3) bat-influenza has both
genetic and protein incompatibility with influenza A or B
viruses, and (4) that these bat-influenza lineages pose little
pandemic threat.
Synthetic Bat-Influenza Virus Is Infectious
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indicate that the HA doesn’t bind to canonical sialic acid receptors
of influenza viruses and the NA doesn’t have neuraminidase
activity, which is characteristic of IAV and IBV NAs [6–9]. To
further examine if the HA and NA proteins are the major blocks to
the propagation of the Bat09 virus, we attempted to rescue
reassortant viruses that contained the 6 internal protein coding
vRNAs (PB2, PB1, PA, NP, M, and NS) from Bat09 and the
surface glycoprotein vRNAs (HA and/or NA) from a recombinant
A/Puerto Rico/8/1934 (PR8). PR8 is a lab adapted H1N1 virus
that has been used for many years in research and vaccine settings
because it replicates efficiently in embryonated chicken eggs, cell
lines (e.g., MDCK) and in the mice, but has low risk to humans.
However, the three PR8-HA/NA reassortant genotypes contain-
ing the Bat09 internal protein vRNAs couldn’t be rescued
following transfection (Fig. 1B). While the Bat09 internal
protein/vRNAs are capable of generating proteins and producing
influenza-like particles, they may have critical mutations that were
inhibiting infectivity, or they can’t cooperate efficiently with the
PR8-HA/NA proteins/vRNAs.
Modified bat-influenza virus could be generated and it
replicated efficiently in vitro, in ovo, and in vivo
To further address the inability to rescue Bat09 or the
Bat09:PR8-HA/NA reassortants, we created a modified HA
vRNA (mH1) that contained the protein coding region from PR8-
H1 flanked by putative cis-acting terminal packaging signals from
Bat09 that we hypothesized would be similar to the regions known
to be central to packaging of A/WSN/1933 and PR8 [12,13]
(Fig. 1C and Fig. S2). The Bat09 NA gene segment was
modified using a similar strategy to replace the NA coding region
with PR8-N1, while the putative bat NA packaging signals were
retained (mN1) (Fig. 1C and Fig. S2). Co-expression of the mH1
and mN1 vRNAs with the six Bat09 internal protein vRNAs
efficiently rescued a reassortant Bat09:mH1mN1 virus (Fig. 1B).
The reassortant Bat09:mH1mN1 formed particles similar to that
of Bat09 (Fig. 1A) and replicated robustly in vitro and in ovo
(Fig. 1D, 1E). Next generation sequencing demonstrated that the
consensus sequence of the virus stocks from 1 passage in MDCK
cells or embryonated chicken eggs was identical to that of the
reverse genetics plasmids. Furthermore, even after 3 passages in
MDCK cells, we still didn’t identify any nucleotide polymorphisms
accounting for .10% of the genomic population that would
suggest strong selective pressure on Bat09 genes or the modified
HA/NA genes of PR8.
To investigate whether Bat09:mH1mN1 is able to infect and
replicate in mice, a mouse study was performed using the mouse
adapted PR8 IAV as a positive control. Bat09:mH1mN1
replicated efficiently in mouse lungs (Fig. 2A), and caused
significant weight loss as early as at 4 days post inoculation
(4 dpi) (Fig. 2B). The virulence of Bat09:mH1mN1 (75%
mortality) was close to that of the PR8 virus (100% mortality)
(Fig. 2C). Histopathological analysis showed that the
Bat09:mH1mN1 virus caused typical influenza-like lesions char-
acterized by a varying degree of broncho-alveolar epithelial
degeneration and necrosis, and interstitial pneumonia. The
peribronchiolar and perivascular areas were infiltrated by mod-
erate numbers of lymphocytes and plasma cells (Fig. 2D). The
histopathology identified correlates with presence of virus antigen
in the mouse lungs (Fig. 2E).
Next generation sequencing was used to determine if the Bat09
vRNAs were genetically stable in mice. Although nucleotide
polymorphisms (at the level of 12%–36%) were detected at
sporadic loci throughout the Bat09 vRNAs, each lung sample only
had one such polymorphism on average, and none of the
mutations were found in more than one mouse. Nonetheless,
serial passage of this virus in mice may identify mutations in the
Bat09 backbone critical to replication/pathogenesis in mice. We
did identify a low level nucleotide polymorphism in the modified
PR8 HA at residue at 187 that emerged in multiple
Bat09:mH1mN1 inoculated mouse lung samples collected at 3
and 5 dpi (HA-K187E, 10%–20% of the genomic population).
This unanticipated result may have also occurred in PR8
inoculated mice; however the lung specimens from these mice
were not sequenced.
The virulence of the Bat09:mH1mN1 in mice could partly
result from the H1 and N1 of the mouse adapted PR8 virus. To
further investigate pathogenicity of Bat09-like viruses we rescued
another modified Bat09 virus that expresses H3N2 surface
glycoproteins from A/swine/Texas/4199-2/1998 (H3N2)
(TX98), which we have used in pigs previously [14]. The HA/
NA vRNAs of Bat09:mH3mN2 were modified using a similar
strategy used to generate the mH1/mN1, whereby the coding
regions of Bat09 glycoproteins were replaced with TX98 H3N2,
while the putative Bat09 packaging signals were retained (mH3/
mN2) (Fig. 3A). The rescued Bat09:mH3mN2 virus replicated to
peak titers close to that of TX98 (Fig. 3B) and both viruses were
inoculated into mice to compare the morbidity (weight loss),
mortality and virus replication at various times post inoculation.
All mice survived infection and both viruses (Bat09:mH3mN2 and
TX98) caused little effect on weight gain as compared to the mock
inoculated animals (Fig. 3C), indicating little overall disease.
Titration of virus in the lung tissues showed that the
Bat09:mH3mN2 virus replicated as efficiently as the TX98 control
in the mice at early time points, yet it appeared to be cleared more
rapidly (Fig. 3D). This data suggests that some of the pathoge-
nicity observed in the Bat09:mH1mN1 infected mice likely results
from the mouse adapted HA/NA of PR8. However, it is clear that
the bat influenza internal protein vRNAs do support replication of
the modified viruses (Bat09:mH1mN1 and Bat09:mH3mN2) in
vitro, in ovo, and in the mouse lungs. The slightly lower replication
efficiency and pathogenicity of those two viruses compared to the
corresponding PR8 and TX98 viruses could be ascribable to either
the nature of the Bat09 internal protein vRNAs or the engineering
of the modified HAs and NAs.
Bat-influenza NS1 shows strong innate immune
suppression in human cells and in mice
Bat-influenza viruses appear to have diverged from IAV a very
long time ago and their internal protein vRNAs have many unique
features that are not seen in IAVs [3,4]. Therefore, the biological
roles of the various vRNA segments and their protein products are
likely to have both similarities and intriguing differences. Many
deadly bat viruses (e.g., filoviruses) have evolved powerful
molecular mechanisms that inhibit host (e.g., human) immune
responses [15–18]. Therefore, to gain an understanding of how
bat-influenza viruses may evade the host innate immune response
we analyzed the Bat09 NS1 protein using interferon induction
experiments and carboxy-terminal truncation mutations known to
attenuate IAVs. The NS1 protein of IAVs is critical for
pathogenicity of many strains because of its ability to antagonize
the host interferon response [19]. To compare the direct effect of
Bat09-NS1 and PR8-NS1 on interferon-b production, we
expressed the proteins ectopically in human HEK-293T and then
infected them with Sendai virus to stimulate the innate immune
response. Activation of interferon-b promoter was determined by a
luciferase mediated reporter assay [16]. Bat09-NS1 inhibited host
interferon-b induction comparable to that of the PR8-NS1, and
carboxy-terminal truncation of Bat-NS1 protein (NS1-128 and
Synthetic Bat-Influenza Virus Is Infectious
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NS1-73, see Fig. S2C for diagram) decreased its ability to inhibit
interferon-b production (Fig. 4A). These results are consistent
with the attenuating effect that these NS1 truncations have on PR8
(Fig. 4A) and other IAV NS1 proteins; thereby, providing a
strategy to generate live attenuated influenza vaccines [14,20–22].
A VSV-luciferase virus mediated bioassay was also performed to
compare the effect the NS1 truncations have on the Bat09 viruses’
ability to inhibit host innate immune response [22]. The
replication of the VSV-luciferase virus, which is sensitive to innate
immune activation, is inversely correlated with type I interferon
induced by influenza virus. Truncation of the Bat09-NS1 modestly
reduced VSV replication, whereas truncation of the PR8-NS1
severely inhibited VSV replication (i.e., luciferase expression)
(Fig. 4B). These results were confirmed by analysis of influenza
virus replication kinetics in a human lung epithelial cell line
(Fig. 4C). The Bat09-NS1 truncated viruses (Bat09:mH1mN1ss-
NS1-128 and Bat09:mH1mN1ss-NS1-73) replicated to titers of
106–107 TCID50/ml (near wild type NS1; Bat09:mH1mN1ss),
whereas the PR8-NS1 truncation mutants had 100–1000 fold lower
titers than PR8 (Fig. 4C, Fig. S2 for gene and virus diagrams).
To analyze the impact of these Bat NS1 truncation mutations in
vivo we inoculated mice with the same panel of modified Bat09
viruses, or the PR8-NS1-126 as a control. In contrast to the
significant attenuation conferred by the truncated NS1 in PR8
(PR8-NS1-126), recombinant bat-influenza viruses with truncated
NS1 genes (Bat09:mH1mN1ss-NS1-128 and Bat09:mH1m
N1ss-NS1-73) replicated efficiently in the lungs (Fig. 5A), caused
significant morbidity (Fig. 5B), and remained 100% lethal in mice
(Fig. 5C). Altogether the NS1 studies show that the Bat09 NS1
protein inhibits host interferon-b production and carboxy-terminal
Figure 2. Pathogenicity of Bat09:mH1mN1 and PR8 viruses in mice. (A) Virus titers of Bat09:mH1mN1 and PR8 in mouse lungs at 3 and 5 dpi.
Each mouse was intranasally inoculated with 103 TCID50 of each virus. (B) Mouse weight on each day post inoculation was represented as a
percentage of the weight on day 0 (100%). Each mouse was intranasally inoculated with 104 TCID50 of Bat09:mH1mN1 or PR8. (C) Survival rate of the
mice inoculated with 104 TCID50 of virus. (D) H&E staining of microscopic lung sections from mice inoculated with 10
3 TCID50 of virus at 5 dpi. (E) IHC
staining of lung sections at 5 dpi. *, P,0.05, Bat09:mH1mN1 compared to PR8.
doi:10.1371/journal.ppat.1004420.g002
Synthetic Bat-Influenza Virus Is Infectious
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truncation mutations reduce its ability to antagonize this response,
likely through mechanisms similar to IAV (Fig. 4A). However, in
contrast to IAV, truncation (NS1-128, NS1-73) of the Bat09 NS1
didn’t dramatically impact the viruses’ ability to antagonize the host
innate response, or replicate and cause disease in mice (Fig. 4B, C
and Fig. 5).
Pathogenesis of the modified Bat09 virus can be
manipulated by amino acid substitutions at residues
important in virulence of IAVs
We analyzed the Bat09 PB2 gene because of its central role in
the species specificity of IAVs, and some of the critical residues
involved are known to be virulence determinants in mice and
ferrets [23–28]. Asparagine (N) 701 in the PB2 protein is a
mammalian-signature in IAVs and when this residue was mutated
to aspartic acid (D, an avian-signature) in the modified Bat09
(Bat-701D), it decreased virus titers in lungs, morbidity (minor
weight loss), and resulted in 100% survival (Fig. 6). The bat-
influenza PB2 also has a serine (S) residue at position 627, which is
unlike either mammalian or avian IAVs. Replacing the serine 627
with the mammalian-signature residue lysine (K) [24,27] in the
context of 701D (Bat-627K/701D) increased virus replication in
the lungs but only caused slightly more weight loss (compared to
the Bat-701D virus) and it remained attenuated in mice (Fig. 6).
In contrast, introducing another virulence marker PB2-E158G
[23] into the PB2-N701D virus (Bat-158G/701D) dramatically
increased the pathogenicity of the Bat09 virus (100% mortality),
which was higher than the Bat09 virus with wild type PB2
(Bat09:mH1mN1, Fig. 6). In addition, introducing the PB2-
E158G (Bat-158G) into the wild type PB2 resulted the most
significant increase of virus replication, morbidity, and mortality
(Fig. 6), indicating there is an additive effect between the two
virulence determinants (PB2-158G and PB2-701N) in the Bat09
PB2. All viruses collected from mouse lungs were deep sequenced
to confirm the stability of the engineered mutations and although
sporadic nucleotide polymorphisms (10% - 44%) were detected in
the viral genomes (1 to 2 such polymorphisms per mouse sample
on average), none of them occurred at the engineered loci. The
high genetic stability of the modified Bat09 viruses in mice is
consistent with the notion that the bat influenza viruses are
mammalian viruses that have been evolving and adapting in the
bats for a long period of time.
To determine the molecular basis for the altered pathogenicity
imparted by the various mutations in the PB2 we examined their
effects on the viral polymerase activity in human 293T cells using a
luciferase-mediated mini-genome replication assay (Fig. 7). At all
temperatures tested, the PB2-N701D mutation decreased the
polymerase activity and the PB2-E158G mutation enhanced the
polymerase activity, consistent with the decreased and increased
pathogenicity in mice, respectively (Fig. 6). Interestingly, the PB2-
627S showed intermediate polymerase activity compared to the
PB2-627K and PB2-627E (Fig. 7). In addition, the polymerase
activity of the PB2-158G and PB2-627E/K mutants decreased
proportionally when they were combined with the PB2-701D
mutation (Fig. 7). This result is consistent with the observation
that Bat-158G/701D appeared to be less pathogenic than the Bat-
Figure 3. Diagram of the Bat09:mH3mN2 construct, and pathogenicity of Bat09:mH3mN2 and TX98 viruses in mice. (A) Modified HA
(mH3) and modified NA (mN2). To construct the mH3, TX98-HA coding region was flanked by the putative packaging regions from Bat09-HA and all
potential start codons in the Bat09-HA 59 packaging region were mutated. To construct the mN1, PR8-NA coding region was flanked by the putative
packaging regions from Bat09-NA and all start codons in the Bat09-NA 59 packaging region were mutated. (B) Bat09:mH3mN2 and TX98 replication
kinetics in MDCK cells. MDCK cells were inoculated at a multiplicity of infection (MOI) of 0.01 TCID50/cell with the Bat09:mH3mN2 or TX98 viruses. (C)
Weight loss of mice mock-infected or infected with Bat09:mH3mN2 or TX98 viruses. Each mouse was intranasally inoculated with 36105 TCID50 of
each virus. (D) Virus titers of Bat09:mH3mN2 and TX98 viruses in mouse lungs at 3 and 5 dpi. Each mouse was intranasally inoculated with 36104
TCID50 of each virus. *, P,0.05, Bat09:mH3mN2 compared to TX98.
doi:10.1371/journal.ppat.1004420.g003
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PLOS Pathogens | www.plospathogens.org 5 October 2014 | Volume 10 | Issue 10 | e1004420
158G virus (Fig. 6). Collectively, the data collected on the Bat09
PB2 show that amino acid residues known to be important in
replication, species specificity, transmission, and/or pathogenesis
of IAV are important in the replication and pathogenesis of Bat09.
Internal protein-coding vRNAs of bat-influenza don’t
efficiently reassort with IAV or IBV
Reassortment of IAVs is important in the evolution of IAVs and
generation of panzootic and pandemic strains. Furthermore,
efficient replication of bat-influenza internal protein vRNAs in
Figure 4. In vitro property of Bat-NS1 mutants. (A) Luciferase
reporter mediated assay to quantitate the NS1 protein inhibition effects
on interferon-b promoter activation. (B) VSV-luciferase mediated
bioassay to quantitate the inhibitory effects on VSV virus infection
resulted from the immune response induced by the different NS1 WT or
truncated viruses. (C) Virus replication kinetics in human lung epithelial
Calu-3 cells. * or #, P,0.05, Bat-NS1-128 compared to PR8-NS1-126 (*)
and Bat-NS1-73 compared to PR8-NS1-73 (#) are shown in (B) and (C).
doi:10.1371/journal.ppat.1004420.g004
Figure 5. Pathogenicity of Bat-NS1 mutants in mice. (A) Virus
titers of Bat09:mH1mN1ss and NS1 mutants in mouse lungs at 3 and
5 dpi. Each mouse was intranasally inoculated with 104 TCID50 of each
virus. (B) Mouse weight on each day post inoculation was represented
as a percentage of the weight on day 0 (100%). Each mouse was
intranasally inoculated with 105 TCID50 of the indicated viruses. (C)
Survival rate of the mice inoculated with 105 TCID50 of the viruses.
Higher virus doses were used in this experiment based on the PR8-NS1-
126 control virus, which caused significant weight loss but had low
mortality at 105 TCID50 so the attenuation of Bat-NS1 truncated viruses
can be appropriately compared to it. *, P,0.05, truncated
Bat09:mH1mN1ss-128 and Bat09:mH1mN1ss-73 compared to PR8-
NS1-126.
doi:10.1371/journal.ppat.1004420.g005
Synthetic Bat-Influenza Virus Is Infectious
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human cells and mice, as well as their pathogenicity, necessitated
an assessment of reassortment potential between Bat09 and other
influenza viruses. Replication of vRNAs from different parental
viruses is a factor critical in the generation of reassortant progeny.
Transcription/replication of mini-genome reporter constructs
showed that the viral RNA dependent RNA polymerase (RdRp),
which is a heterotrimer of PB1, PB2, and PA, from bat-influenza,
IAVs, and IBVs generally recognize and transcribe their cognate
vRNAs more efficiently than non-cognate vRNAs (Fig. S3).
Intriguingly, the Bat09 polymerase replicated the IBV reporter
very efficiently (Fig. S3). Additionally, most RdRp combinations
(PB2, PB1, PA) between bat-influenza and IAVs nearly abolished
the polymerase activity in this very sensitive mini-genome report-
er assay (Fig. 8A–I). Interestingly, the NP protein, which is a
Figure 6. Pathogenicity of Bat-PB2 mutants in mice. (A) Virus
titers of Bat09:mH1mN1 and PB2 mutants in mouse lungs at 3 and
5 dpi. Each mouse was intranasally inoculated with 103 TCID50 of each
virus. (B) Mouse weight on each day post inoculation was represented
as a percentage of the weight on day 0 (100%). Each mouse was
intranasally inoculated with 104 TCID50 of the indicated viruses. (C)
Survival rate of the mice inoculated with 104 TCID50 of the viruses. *, P,
0.05, PB2 mutants compared to Bat09:mH1mN1. For mouse body
weight, * is only marked on the first day of each group that is
significantly different from Bat09:mH1mN1.
doi:10.1371/journal.ppat.1004420.g006
Figure 7. Polymerase activity of Bat09 with wild type and
mutant PB2. A luciferase mediated mini-genome replication assay was
performed at 33uC, 37uC, and 39uC by co-transfecting 293T cells with
Bat09 PB2 (WT or mutant), PB1, PA, NP, and a vRNA-like luciferase
reporter. Relative luciferase activity were determined to represent the
viral polymerase activity. *, P,0.05, compared to WT.
doi:10.1371/journal.ppat.1004420.g007
Synthetic Bat-Influenza Virus Is Infectious
PLOS Pathogens | www.plospathogens.org 7 October 2014 | Volume 10 | Issue 10 | e1004420
Figure 8. Compatibility of the PB2, PB1, PA and NP originated from Bat09 and other influenza viruses. A mini-genome replication assay
was used to determine the compatibility of the different RdRp components. (A–I) PB2, PB1, PA, and NP from Bat09 and various influenza A viruses as
indicated. (J) PB2, PB1, PA and NP from Bat09 and B/Russia/69. (K) PB2, PB1, PA and NP from Bat09 and Bat10. The vRNA reporters used for the
compatibility test between Bat09 and IAVs (Fig. 8A–I) were an equal ratio of pPolI-Bat-NS-Luc and pPolI-FluA-NS-Luc. For compatibility test between
Bat09 and IBV (Fig. 8J) the vRNA reporters used were pPolI-Bat-NS-Luc and pPolI-FluB-NS-Luc. For compatibility test between Bat09 and Bat10
(Fig. 8K) only the pPolI-Bat-NS-Luc plasmid was used.
doi:10.1371/journal.ppat.1004420.g008
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single-strand RNA-binding nucleoprotein, is completely compat-
ible between Bat09 and IAVs (Fig. 8A–I), but it is incompatible
between the bat-influenza and IBV (Fig. 8J).
Although some gene segment combinations showed limited
polymerase activity in the mini-genome assays, we couldn’t
generate any reassortant viruses using reverse genetics between
Bat09:mH1mN1 and PR8 that contain partly compatible RdRp
components (e.g., Bat-PB2/PR8-PB1/PR8-PA), including the
highly compatible NP vRNA/protein (Table 1 and Table 2).
Instead, the PR8-M segment could unidirectionally substitute for
the Bat09-M segment (Table 2). This likely results from the
highly conserved nature of the M vRNA and proteins (M1, M2).
Swapping the putative cis-acting packaging signals of the Bat-NP
and known packaging signals of the PR8-NP, or between the Bat-
NS and PR8-NS didn’t enable rescue of viruses containing either
the NP or NS vRNAs in a heterologous virus background
(Table 3 and see Fig. S2 for diagrams).
HA and NA vRNAs of bat and other influenza viruses have
limited compatibility
Low efficiency of packaging at least some vRNA segments from
the heterologous virus is also a major restrictive factor for
reassortment. For instance, a reassortant virus containing six
internal protein vRNAs from Bat09 and the HA and NA from
PR8 couldn’t be rescued, whereas the PR8 HA and NA coding
regions flanked by Bat09 packaging regions (mH1 and mN1) can
efficiently reassort with the Bat09 internal genes (Fig. 1B and
Table 4). Nevertheless, PR8 HA and NA can individually
reassort (7:1) with the Bat09 six internal protein vRNAs when
mN1 or mH1 were provided, respectively (Table 4). The inability
to rescue the 6:2 reassortant Bat09:PR8-H1N1 virus may result
from compounding the low efficiency of packaging for each of the
wild type PR8-HA and PR8-NA vRNAs into the bat-influenza
backbone.
The mN1 can also reassort with the other seven segments from
PR8, even when many silent substitutions (ss) were introduced into
the N1 coding regions to disrupt the remaining PR8 packaging
signals (Table 4). Actually, another modified NA that contains
the coding region from IBV NA flanked by the putative packaging
region of the Bat09-NA (Bat-N10ps-FluB-NA) can also be rescued
in the PR8 background, strongly suggesting that the bat-influenza
NA segment could be efficiently packaged into the PR8 virus,
whereas the Bat09 HA packaging signal didn’t mediate efficient
packaging of the mH1 into the PR8 backbone (Table 4).
Interrogation of reassortment between IAV and modified
Bat09 using a classical co-infection approach
While the generation of reassortants through plasmid-based
reverse genetics is a powerful and sensitive way to rescue influenza
viruses, it’s difficult to generate every possible gene constellation
and accompanying minor nucleotide variations that could give rise
to progeny reassortants during co-infection. Therefore, we
attempted to generate reassortants between a modified Bat09
virus and PR8 using a classical co-infection approach. However,
when MDCK cells were inoculated at a high multiplicity of
infection (MOI) with both PR8 and Bat09:mH1mN1 viruses,
reassortment between the two parental viruses was not detected.
We plaque purified 118 progeny viruses from the co-infection and
53 of them were the parental PR8 virus and 65 of them were the
parental Bat09:mH1mN1 virus. Although more exhaustive
classical reassortant studies are needed to completely evaluate
the generation of natural reassortants between these viruses, the
data indicate that PR8 and Bat09:mH1mN1 don’t efficiently
reassort.
Table 1. Rescue efficiency of PB2, PB1, PA reassortants between Bat09:mH1mN1 and PR8.
PB2 PB1 PA NP,M,NS HA,NA Rescue*
1 Bat Bat Bat Bat mH1,mN1 ++++
2 PR8 Bat Bat Bat mH1,mN1 Neg
3 Bat PR8 Bat Bat mH1,mN1 Neg
4 Bat Bat PR8 Bat mH1,mN1 Neg
5 PR8 PR8 Bat Bat mH1,mN1 Neg
6 PR8 Bat PR8 Bat mH1,mN1 Neg
7 Bat PR8 PR8 Bat mH1,mN1 Neg
8 PR8 PR8 PR8 Bat mH1,mN1 Neg
9 Bat Bat Bat PR8 PR8 Neg
10 PR8 Bat Bat PR8 PR8 Neg
11 Bat PR8 Bat PR8 PR8 Neg
12 Bat Bat PR8 PR8 PR8 Neg
13 PR8 PR8 Bat PR8 PR8 Neg
14 PR8 Bat PR8 PR8 PR8 Neg
15 Bat PR8 PR8 PR8 PR8 Neg
16 PR8 PR8 PR8 PR8 PR8 ++++
*Rescue efficiency definition.
Very easy (++++): P0 viral titer 106–108 TCID50/ml, or severe CPE observed in P1 within 1 dpi;
Moderate (+++): P0 titer 104–106 TCID50/ml, or obvious CPE observed in P1 within 2 dpi;
Difficult (++): P0 titer 102–104 TCID50/ml, or weak CPE observed in P1 within 4 dpi;
Very difficult (+): P0 titer lower than 102 TCID50/ml, or CPE not observed until P2/P3;
Negative (Neg): rescue failed, no CPE observed through passage 3.
For each combination, the rescue was repeated at least 3 times.
doi:10.1371/journal.ppat.1004420.t001
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Divergent bat-influenza viruses are highly compatible for
reassortment
Recently, another bat-influenza virus A/flat-faced bat/Peru/
033/2010 (H18N11) (Bat10) was identified in Peru and phylo-
genetic analysis indicated this virus diverged from the bat-
influenza viruses identified in Guatemala (e.g., Bat09) so long
ago that genetic diversity between these two bat-influenza viruses
is higher than that of IAVs [4]. Reassortment of the PB2, PB1, PA,
and NP segments in mini-genome polymerase activity assay
demonstrated that the Bat09 and Bat10 viruses were fully
compatible (Fig. 8K). Most importantly, successful reassortment
between the two modified bat viruses (Bat09:mH1mN1ss and
Bat10:mH1mN1ss) (Table 5 and Fig. S2 for diagrams of
constructs) proved that these genetically divergent bat-influenza
virus vRNAs were highly interchangeable, in contrast to their very
low compatibility with IAV and IBV. Interestingly, classical co-
infection of the Bat09:mH1mN1 and Bat10:mH1mN1 viruses in
MDCK cells readily generated reassortant progeny viruses with
various genotypes, and some were apparently preferentially
selected (e.g., Bat10:Bat09-NS reassortant, Table S2), demon-
strating the merit of classic co-infection strategy in identification of
gene constellations that may have certain advantages. Collectively
the mini-genome replication, reverse genetics reassortment, and
co-infection reassortment experiments strongly suggest that two
divergent bat-influenza viruses readily reassort with each other,
whereas they won’t reassort with canonical IAVs in the natural
setting.
Discussion
The generation of synthetic modified bat-influenza viruses (e.g.,
Bat09:mH1mN1) that grow to high titers in commonly used
influenza virus culture substrates and mice is an important step
toward understanding these novel bat-influenza viruses. The
Table 2. Rescue efficiency of internal gene reassortants between Bat09:mH1mN1 and PR8.
Pols* NP M NS HA,NA Rescue**
1 Bat Bat Bat Bat mH1,mN1 ++++
2 Bat Bat Bat PR8 mH1,mN1 Neg
3 Bat Bat PR8 Bat mH1,mN1 +++
4 Bat Bat PR8 PR8 mH1,mN1 Neg
5 Bat PR8 Bat Bat mH1,mN1 Neg
6 Bat PR8 Bat PR8 mH1,mN1 Neg
7 Bat PR8 PR8 Bat mH1,mN1 Neg
8 Bat PR8 PR8 PR8 mH1,mN1 Neg
9 PR8 Bat Bat Bat mH1,mN1 Neg
10 PR8 Bat Bat PR8 mH1,mN1 Neg
11 PR8 Bat PR8 Bat mH1,mN1 Neg
12 PR8 Bat PR8 PR8 mH1,mN1 Neg
13 PR8 PR8 Bat Bat mH1,mN1 Neg
14 PR8 PR8 Bat PR8 mH1,mN1 Neg
15 PR8 PR8 PR8 Bat mH1,mN1 Neg
16 PR8 PR8 PR8 PR8 mH1,mN1 Neg
17 Bat Bat Bat Bat PR8 Neg
18 Bat Bat Bat PR8 PR8 Neg
19 Bat Bat PR8 Bat PR8 Neg
20 Bat Bat PR8 PR8 PR8 Neg
21 Bat PR8 Bat Bat PR8 Neg
22 Bat PR8 Bat PR8 PR8 Neg
23 Bat PR8 PR8 Bat PR8 Neg
24 Bat PR8 PR8 PR8 PR8 Neg
25 PR8 Bat Bat Bat PR8 Neg
26 PR8 Bat Bat PR8 PR8 Neg
27 PR8 Bat PR8 Bat PR8 Neg
28 PR8 Bat PR8 PR8 PR8 Neg
29 PR8 PR8 Bat Bat PR8 Neg
30 PR8 PR8 Bat PR8 PR8 Neg
31 PR8 PR8 PR8 Bat PR8 Neg
32 PR8 PR8 PR8 PR8 PR8 ++++
*Pols = Co-transfection of PB1, PB2, and PA reverse genetics plasmids.
**Rescue efficiency defined in Table 1. For each combination, the rescue was repeated at least 3 times.
doi:10.1371/journal.ppat.1004420.t002
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rescue of Bat09:mH1mN1 and Bat09:mH3mN2 viruses demon-
strates that the putative vRNAs of Bat09 function efficiently
together and are probably derived from either one virus, or a
group of compatible viruses, whose PB2, PB1, PA, NP, M, and NS
proteins efficiently replicate and package vRNAs in host cells
commonly used to culture influenza viruses (Fig. 1). Importantly,
the data also shows that the bat-influenza HA and NA were the
sole determinants inhibiting Bat09 virus rescue, and that the
terminal regions of HA and NA of bat-influenza viruses selected
for our constructs contain cis-acting vRNA packaging signals.
Although wild type bat-influenza virus (Bat09) couldn’t be
propagated in the human, canine, mink, avian, porcine or bat
cell lines we tested, consistent with Tong et al. [3], it is likely that
the bat-influenza virus can infect some other cell cultures from
other species and/or tissues, especially cells derived from
appropriate bat species.
Our Bat09:mH1mN1 studies provide other unique insights,
which can’t be gleaned from non-infectious assays. For instance,
non-infectious assays (interferon-b reporter assay, Fig. 4A)
showed the Bat09 NS1 carboxy-terminal truncationss (NS1-128
and NS1-73) were similar to the truncated PR8 NS1 (NS1-126
and NS1-73), which largely lost the ability to inhibit the host
interferon response. However, mouse experiments with the
replicative bat-influenza viruses revealed that the truncation of
Bat09 NS1 had minimal effects on the viral pathogenesis
compared to the truncation of PR8 NS1 (Fig. 5). Differences in
the attenuating impact observed in the PR8-NS1 and the Bat09-
NS1 truncated viruses suggests that Bat09 has novel molecular
mechanisms that have evolved in the amino terminal portion of
NS1 and/or other internal protein vRNAs to antagonize/evade
the host innate immune response.
The PB2 of IAV plays important roles in replication, species
specificity, transmission, and pathogenesis [23–29]. Our analysis of
bat-influenza PB2 demonstrated that it is also a virulence
determinant and as anticipated conversion of mammalian-
signature residues at position 701 to avian-signature (N701D)
attenuated the virus, and the E158G substitution [23] enhanced
virulence. PB2-627 is one of the most studied positions differen-
tiating avian viruses (glutamic acid) and mammalian viruses
(lysine) [24,27]. Intriguingly, the bat-influenza PB2 has a serine at
position 627, which is unlike mammalian or avian IAVs. Our data
show that PB2-627S has intermediate polymerase activity com-
pared to PB2-627E and PB2-627K in mammalian cells, suggesting
an alternative evolutionary pathway that avian influenza viruses
may be able to take for mammalian adaptation.
Reassortment of the segmented genomes of Orthomyxoviruses is
a powerful evolutionary mechanism that is central to the success of
these pathogens. Viruses within a Genus readily reassort upon co-
infection of a single host cell (e.g., avian and swine IAV); whereas,
viruses from a different Genus (e.g., IAV and IBV) don’t reassort.
The factors important for generation of reassortant progeny from
two parental influenza viruses include: recognition and replication
of vRNAs by parental virus RdRp, protein-protein interaction/
compatibility (e.g, heterotrimeric RdRp), and vRNA-protein
interactions needed for virion morphogenesis. The RNA tran-
scription/replication promoter of each influenza vRNA segment is
formed by base pairing of highly conserved nucleotides at the 59
and 39 termini, which form a partially double-stranded structure.
The IAV Genus has specific nucleotide variations within the
termini that distinguish it from IBV. The termini of bat-influenza
vRNAs also show conserved 59 and 39 complementarity; however,
they also have distinct nucleotide variation. Therefore, we used
mini-genome replication studies to analyze promoter recognition
and RdRp activity of various combinations of the PB1, PB2, PA
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subunits in combination with various NPs from IAV, IBV, or bat-
influenza. The data show that the wild type RdRp most efficiently
replicate their cognate vRNAs, and that both IAV and IBV RdRp
have 50–60% reduction in activity with the bat-influenza mini-
genome. Many PB1, PB2, PA combinations between bat-influenza
and IAV/IBV dramatically reduce activity, which demonstrates
protein-protein incompatibility between the RdRp subunits.
Interestingly, the bat-influenza NP and IAV NP were completely
compatible in the mini-genome assay, however NP reassortant
viruses could not be generated (Table 2 and Table 3) suggesting
that the incompatibility of NPs may also involve complicated
protein-vRNA interactions.
IAVs of various subtypes can infect and reassort in bat cell lines
[30,31], providing a permissive environment for them to reassort
with bat-influenza viruses. However, our reassortant analysis
indicates that while two divergent bat-influenzas readily reassort,
bat-influenza and IAVs don’t easily reassort in co-infection
experiments. Reverse genetics reassortment studies showed the
PB2, PB1, PA, NP, and NS vRNAs of bat-influenza don’t
efficiently reassort with the IAV or IBV, and provide many
additional tantalizing results. For example, reassortants were not
rescued from relatively compatible RdRp combinations in the
mini-genome assay (e.g. Bat-PB2/PR8-PB1/PR8-PA, Fig. 8A)
and demonstrate that divergent Bat09 and Bat10 can efficiently
reassort with each other (Table 5). The M segment is the most
highly conserved gene among influenza A and B viruses. We found
that the PR8-M segment could substitute for the Bat09-M segment
(Table 2), indicating that the M vRNAs/protein(s) of PR8 and
Bat09 have enough conservation in both cis-acting packaging
signals and functional domains of the proteins (M1/M2) to enable
the replication of the modified Bat09 virus. In contrast, putative
packaging signal swapping of the NP and NS segments didn’t
overcome reassortment defects suggesting that incompatibility at
the protein-protein or protein-vRNA level is likely to be a critical
factor inhibiting reassortment between the bat-influenza and other
influenza viruses. Alternatively, one could argue that that since the
vRNA packaging signals of bat-influenza NP and NS segments
have not been delineated, the putative packaging regions
incorporated in the Batps-PR8 constructs may not be sufficient
for packaging the modified vRNAs. However, the well-defined
PR8 packaging signals incorporated in our modified gene
segments should be sufficient to package the corresponding
bat-influenza NP and NS vRNAs (PR8ps-Bat-NP and PR8ps-
Bat-NS, Fig. S2D) in the PR8 backbone. The failure to rescue the
PR8ps-Bat NP or NS viruses, as well as the PR8:Bat09-M
reassortant virus, strongly suggests protein-protein or protein-
vRNA level incompatibility and provides a unique opportunity to
better understand the functional domains of these proteins through
characterizing chimeric/mosaic proteins containing motifs/do-
mains from both viruses.
Another caveat with our bat-influenza reassortment experi-
ments is the focus on interactions with the laboratory adapted PR8
virus, which was chosen primarily due to biosafety concerns.
Reassortment between the Bat09:mH1mN1 virus and other IAVs,
particularly avian viruses (e.g., H5N1, H7N9) that appear to be
more compatible in the mini-genome assay (Fig. 8), are needed to
fully assess reassortment potential of bat-influenza. However,
based on our results from the NP reassortment and the Bat-PB2/
PR8-PB1/PR8-PA reassortment experiments (Table 1 and
Table 2), the likelihood of rescuing a reassortant with RdRp
components from both Bat and IAVs is very low. Finally, since the
HAs and NAs of the bat influenza viruses can’t be used to rescue
viruses using contemporary influenza virus host substrates, we
were not able to fully assess the ability of the HA or NA to reassort
with other influenza viruses (limited assessment provided in
Table 4). However, the known bat influenza viruses (Bat09,
Bat10) could pose a pandemic threat if their HA and NA acquire
mutations that impart binding to canonical influenza virus
receptors and rescuing the NA for neuraminidase activity, or
acquisition of binding and entry through alternative human cell
surface receptors.
Collectively, our experiments suggest that the bat-influenza
virus is unlikely to reassort with an IAV or IBV and spread to
other species even if they were to infect the same host cell. The
restriction on reassortment appears to result from multiple levels of
incompatibility (RNA-RNA, RNA-protein, and/or protein-pro-
tein) that are either additive or synergistic. Consequently, our data
suggest that due to the extremely limited ability of genetic
information exchange between bat-influenza and IAV or IBV, the
International Committee on Taxonomy of Viruses could consider
classifying these two bat-influenza virus lineages as a new Genus or
Species within the Orthomyxoviridae.
This study also demonstrated the power of synthetic genomics
in rapid characterization and risk assessment of an emerging virus,
Table 4. Rescue efficiency of reassortants containing HA and NA packaging single from other viruses.
Internal HA NA Rescue*
1 Bat mH1 mN1 ++++
2 Bat PR8 mN1 ++
3 Bat mH1 PR8 +
4 Bat PR8 PR8 Neg
5 PR8 PR8 PR8 ++++
6 PR8 mH1 PR8 Neg
7 PR8 PR8 mN1 +++
8 PR8 mH1 mN1 Neg
9 PR8 mH1ss PR8 Neg
10 PR8 PR8 mN1ss +++
11 PR8 mH1ss mN1ss Neg
12 PR8 PR8 Batps/B-NA +++
*Rescue efficiency definition described in Table 1.
doi:10.1371/journal.ppat.1004420.t004
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even when the virus itself is not readily cultured. The synthetic
genomics/reverse genetics strategy employed provides an infinite
supply of wild type bat-influenza particles that can be used to
identify permissive cells or animals. The availability of our
modified bat-influenza virus, opens many other avenues of
investigation and discovery, including, for instance, to gain a
better understanding of cis-acting signals in the vRNAs that are
important in bat-influenza transcription, replication, packaging/
particle morphogenesis, and to use forward genetics to elucidate
viral protein-protein and/or viral protein-host protein interactions.
Finally, continued study of bat-influenza viruses and integration of
data from other contemporary influenza viruses is important in the
elucidation of the evolutionary history of influenza viruses.
Materials and Methods
Biosafety and ethics statement
The study was reviewed and approved by the Institutional
Biosafety Committee at Kansas State University (protocol #903),
and by the institutional biosafety committee at the J. Craig Venter
Institute (protocol # 3414). We conducted the initial studies using
PR8 gene fragments to generate the modified bat-influenza viruses
and to test the reassortment potential because PR8 is a widely used
lab/mouse adapted BSL2 virus that poses very low risk to humans
or livestock. Subsequently, TX98 H3N2 genes were used in a few
experiments because this is a BSL2 swine virus, which we have
used previously and the viruses generated were considered low
risk.
The animal studies were performed in strict accordance with
the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
animal protocol (protocol #3339) was reviewed and approved by
the Institutional Animal Care and Use Committee at Kansas State
University. All animal studies were performed in a Biosafety Level
3 facility located at the Biosecurity Research Institute at Kansas
State University under the approved protocol#3339 following the
American Veterinary Medicine Association guidelines on eutha-
nasia. For virus inoculation, each mouse was anesthetized by
inhaling 4% isoflurane. Mice were euthanized if more than 25% of
weight was lost after virus inoculation. Euthanasia of mice was
conducted by inhaling 4% isoflurane followed by cardiac puncture
and cervical dislocation. No survival surgery was performed, and
all efforts were made to minimize suffering.
Cells
Human embryonic kidney 293T (HEK-293T) cells, mouse
rectum epithelial carcinoma (CMT-93) cells, and African green
monkey kidney (Vero) cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). Madin-Darby canine kidney (MDCK) cells
were maintained in minimum essential medium (MEM) supple-
mented with 5% FBS. Human lung epithelial (A549) cells, bat lung
epithelial (Tb1Lu) cells, mink lung epithelial (Mv1Lu) cells and
swine testis (ST) cells were maintained in MEM supplemented
with 10% FBS. Human lung epithelial (Calu-3) cells were
maintained in MEM supplemented with 10% FBS, 1% nones-
sential amino acids, and 1 mM sodium pyruvate.
Complete genome synthesis and plasmid construction
Nucleotide sequences of the eight gene segments of A/little
yellow-shouldered bat/Guatemala/164/2009 (H10N17) (Bat09)
were retrieved from the GenBank database. A total of 472
oligonucleotides of 56–60 bases in length were designed for
enzymatic assembly of the eight segments. The assembly and error
correction processes were performed as recently described [32,33],
modified with increased time at all extension steps (from 72uC for
1 min to 72uC for 2 min) for efficient assembly of the polymerase
segments. The synthesized segments (Fig. S1) were cloned into the
modified bidirectional influenza reverse genetics vectors
pBZ66A12 [34] using the recombination-based method [35] and
transformed into Stella competent E. coli cells (Clontech).
Colonies were selected and sequenced. The appropriate clones
for each segment were propagated for plasmid preparation and
verified by sequencing. The resulting plasmids are pBZ146A1
(PB2), pBZ147A11 (PB1), pBZ148A20 (PA), pBZ149A30 (HA),
pBZ150A31 (NP), pBZ151A36 (NA), pBZ152A42 (M) and
pBZ153A45 (NS). The whole process only took seven days to
complete. The plasmids containing Bat09 PB2 mutations were
constructed by site-directed mutagenesis using the pBZ146A1 as
template. The NS1 truncation constructs were generated by
Gibson assembly and details of the truncations are diagramed in
Fig. S2C. The modified (m) Bat09 HA and NA (mH1, mN1,
mH1ss, and mN1ss, see Fig. S2A, S2B for diagrams, and Fig. S4
for sequence alignment) were synthetized by Gibson assembly
from oligonucleotides. Silent substitutions (ss) were introduced to
disrupt the putative packaging signals in the PR8 HA and NA
terminal coding regions. The mH1ss and mN1ss are thus more
appropriate than the mH1 and mN1 to assess the HA and NA
packaging signal compatibility between Bat09 and PR8. The
Batps-PR8-NP, PR8ps-Bat-NP, Batps-PR8-NS, and PR8ps-Bat-
NP constructs were constructed similarly and diagramed in Fig.
S2D. As a comparison of the speed of different synthesis strategies,
the eight gene segments of A/flat-faced bat/Peru/033/2010
(H18N11) (Bat10) were synthesized by Genewiz (NJ, USA) in
the vector plasmid of pUC57 based on the GenBank database and
subcloned into pHW2000 vector. The resulting plasmids (pHW-
H18-PB2, pHW-H18-PB1, pHW-H18-PA, pHW-H18-HA,
pHW-H18-NP, pHW-H18-NA, pHW-H18-M and pHW-H18-
NS) were confirmed by sequencing. The whole process took more
than one month. The PB2, PB1, PA and NP genes were also
subcloned into the pDZ vector for use in the mini-genome assay.
Diagrams of the mutant or modified genes of Bat09 and Bat10 are
described in Fig. S2. The pPol1-NS-Luc reporters used in the
mini-genome polymerase activity assay were described in Fig.
S2E. Sequences of all constructs used in this study were confirmed
to ensure absence of unwanted mutations and the GenBank
accession numbers are KM203345-KM203356.
Virus rescue
Briefly, 0.6 mg of plasmid for each gene segment was mixed and
incubated with 15 ml of Mirus TranIT-LT1 (Mirus Bio, Madison,
WI) at 20uC for 20 min. The transfection mixture was transferred
to 90% confluent 293T/MDCK cell monolayers in a 35-mm
tissue culture dish and incubated at 37uC with 5% CO2 for 8 h.
The transfection supernatant was replaced with 3 ml of Opti-Mem
I medium (Life Technologies) supplemented with 0.3% bovine
serum albumin (BSA) fraction V (Life Technologies), 3 mg/ml
tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin
(Worthington, Lakewood, NJ), and 1% antibiotic-antimycotic (Life
Technologies). Three days post-transfection, culture supernatant
(passage 0, P0) was collected and 0.5 ml of that was inoculated into
MDCK cells in 6-well plates at 37uC. Supernatant (P1) was
collected at 4 days post-inoculation (dpi), or when severe
cytopathic effect (CPE) was observed. The P1 supernatant was
further passaged blindly for two passage before determined to be
negative for rescue. Titers of the viruses used in this study were
determined by TCID50 assay in MDCK cells.
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Rescue efficiency definition. Very easy (++++): P0 viral titer
106–108 TCID50/ml, or severe CPE observed in P1 within 1 dpi;
Moderate (+++): P0 titer 104–106 TCID50/ml, or obvious CPE
observed in P1 within 2 dpi; Difficult (++): P0 titer 102–104
TCID50/ml, or weak CPE observed in P1 within 4 dpi; Very
difficult (+): P0 titer lower than 102 TCID50/ml, or CPE not
observed until P2/P3; Negative (Neg): rescue failed, no CPE
observed through passage 3.
Various transfection conditions including different transfection
reagents, temperatures, and incubation time before supernatant
collection were attempted to rescue the wild type Bat09 virus and
the reassortants between Bat09 and PR8. However, none of them
generated any positive rescue results if they were negative under
standard rescue condition described above. Bat09 transfection
supernatants were also transferred to various cells (MDCK, mink
lung Mv1-Lu, swine testis, Vero, A549 cells, Calu-3, bat lung
epithelial Tb1Lu) and embryonated chicken eggs and passaged at
least three times. The real-time RT-PCR assays targeting Bat09
and PR8 M genes were used to confirm negative results (primers
and probes are possible upon request).
Electron microscopy
To determine whether virus particles of Bat09 and other viruses
can be produced by reverse genetics system, a total of thirty-five ml
of transfected 293T cell supernatants for each virus were collected
at 48 hours post transfection and centrifuged at 8000 rpm for
20 minutes to remove the cell debris. Then the clear supernatant
was loaded on 30% (w/v) sucrose in centrifuge tubes and was
concentrated at 27,000 rpm (Optima LE-80K ultracentrifuge,
Beckman Coulter) for 2 hours. The virus pellets was dissolved in
100 ml of water and the viral particles were fixed by incubating
with 0.2% paraformaldehyde at 37uC for 48 hours. The fixed
particles were dipped on a 200 mesh copper grid and the grid was
dried and stained with negative staining before observation under
an electron microscope.
Virus replication in vitro and in ovo
MDCK monolayers in 12-well plates were washed twice with
PBS, and then 2 ml of virus growth medium (VGM) was added to
each well. The cells were inoculated at a multiplicity of infection
(MOI) of 0.01 TCID50/cell with the Bat09:mH1mN1 virus or
PR8 virus (Bat09:mH3mN2 virus or TX98 virus) and incubated at
37uC. Supernatants were collected at 1, 2, and 3 days post
inoculation (dpi). Inoculations of Calu-3 cells were performed
similarly, except that an MOI of 0.02 TCID50/cell was used for
the following viruses: Bat09:mH1mN1ss, Bat09:mH1mN1ss-NS1-
73, Bat09:mH1mN1ss-NS1-128, PR8, PR8-NS1-73, and PR8-
NS1-126. The VGM used for MDCK cells was EMEM
supplemented with 0.15% BSA fraction V, 2 mg/ml TPCK-
trypsin, and 1% antibiotic-antimycotic, and the VGM used for
Calu-3 cells was EMEM supplemented with 0.3% BSA fraction V,
1 mg/ml TPCK-trypsin, and 1% antibiotic-antimycotic. All virus
titers were determined by TCID50 assay using MDCK cells.
Six of 10-day-old embryonated chicken eggs were inoculated
with Bat09:mH1mN1 or PR8 at 103 TCID50/egg. After 2 days
incubation at 35uC, allantoic fluid was collected from each egg and
titrated individually. The 4 eggs with the highest titers in each
virus group was used to calculate the average titer and generate
the graph in Fig. 1E.
Next generation sequencing and analysis
A modified Multi-segment RT-PCR [35,36] was used to
amplify influenza-specific segments. The only modification to the
procedure was the primers used for amplification were changed to
match bat influenza termini. The oligonucleotide primers used
were Uni12/Inf-5G (59-GGGGGGAGCAGAAGCAGG-39) and
Uni13/Inf-1 (59-CGGGTTATTAGTAGAAACAAGG-39). The
M-RTPCR amplicons were used for Illumina Miseq library
construction via Nextera DNA sample prep kit (Illumina, Inc.) and
sequenced using the Illumina MiSeq (Illumina, Inc.) according to
manufacturer’s instructions. SNP variations were identified using
custom software that applies statistical tests to minimize false
positive SNP calls that could be caused by the types of sequence-
specific errors that may occur in Illumina reads identified and
described in Nakamura, et al. [37]. To overcome this problem, the
protocol requires observing the same SNP, at a statistically
significant level, in both sequencing directions. Once a minimum
minor allele frequency threshold and significance level are
established by the user, the number of minor allele observations
and major allele observations in each direction and the minimum
minor allele frequency threshold are used to calculate a p-value
based on the binomial distribution cumulative probability, and if
the p-values calculated in each of the two sequencing directions
are both less than the Bonferroni-corrected significance level, then
the SNP call is accepted. For our analyses, we used a significance
level of 0.05 (Bonferroni-corrected for tests in each direction to
0.025), and a minimum minor allele frequency threshold of 10% of
the read population.
Interferon-b reporter assay
To measure the IFN-antagonist function of NS1, a luciferase-
based, Sendai virus-mediated IFN-b promoter activation assay was
conducted as previously described [16]. Briefly, 293T cells in 24-
well plates were transfected with empty vector (200 ng) or
increasing amounts of wild type (WT) or carboxyl terminal
truncated NS1 from Bat09 and PR8 (2 ng, 10 ng, and 50 ng of
NS1 expression plasmids supplemented with 198 ng, 190 ng, and
150 ng of empty vector, respectively). Also co-transfected were
200 ng of an IFN-b-promoter-luciferase reporter plasmid (pIFNb-
Luc) and 20 ng of a plasmid constitutively expressing Renilla
luciferase (pRL-TK from Promega). At 18 hours post transfection,
cells were infected with Sendai virus to induce the IFN-b
promoter. A dual-luciferase assay was performed at 18 hour post
virus inoculation, and firefly luciferase was normalized to Renilla
luciferase activity. The relative luciferase activity of the group with
empty vector was set as 100%, and the other groups were
presented relative to that.
Interferon bioassay with VSV-luciferase virus
As previously described for the VSV-GFP virus mediated
interferon bioassay [22], in the VSV-Luciferase virus mediated
bioassay, A549 cells were inoculated with one of the wild type or
NS1 truncated viruses at an MOI of 4 TCID50/cell, or were
mock-inoculated; supernatants were then collected at 24 hpi.
Supernatants were treated with UV irradiation to inactivate
viruses and were then transferred to naı¨ve A549 cells. Following
24 h of incubation at 37uC, supernatants were removed, and the
cells were inoculated with VSV-Luciferase virus [38], at an MOI
of 2 TCID50/cell. The firefly luciferase expression in the cells was
measured using the Luciferase Assay System (Promega) at 4 hpi
with VSV-Luciferase.
Mini-genome polymerase activity assay
The luciferase-mediated mini-genome polymerase activity assay
was performed as previously described, using a PolI-driven
reporter plasmid and pDZ-based PB2, PB1, PA, and NP
bidirectional expression plasmids [21,35]. To determine the effects
of PB2 mutations on polymerase activity (Fig. 7) 293T cells were
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co-transfected with 0.2 mg each of the PB2 (WT or mutant), PB1,
PA, NP, and a pPol1-FluA-NS-Luc (firefly luciferase flanked by A/
New York/1682/2009 [23]). As a control for transfection
efficiency, 0.02 mg of the Renilla luciferase plasmid pRL-TK
(Promega) was also co-transfected. After 18 hours of incubation at
33uC, 37uC, and 39uC, luciferase production was assayed using
the dual-luciferase reporter assay system (Promega) according to
the manufacturer’s instructions. Firefly luciferase expression was
normalized to Renilla luciferase expression (relative activity). The
relative activity of the PB2-WT was set as 1 fold, and the relative
activities of the PB2 mutants were presented relative to that
(Fig. 7).
To test the compatibility between RNPs (PB2, PB1, PA, and
NP) and viral RNA promoters from bat-influenza virus (Bat09)
(Fig. S3), IAV (A/PR/8/1934), and IBV (B/Russia/1969), 293T
cells were co-transfected with 0.2 mg each of the PB2, PB1, PA,
NP, and a pPol1-NS-Luc reporter plasmid, followed by incubation
at 37uC for 18 hours. Three reporters were used in this study,
including pPolI-Bat-NS-Luc (firefly luciferase flanked by Bat09 NS
non-coding regions), pPol1-FluA-NS-Luc, and pPolI-FluB-NS-Luc
(firefly luciferase flanked by B/Russia/1969 NS non-coding
regions) (Fig. S2D). For each combination of RNP and pPolI-
NS-Luc reporter (from Bat09, A, or B Type), three independent
replicates were conducted. For each RNP, the luciferase activity
with the reporter from the same virus (e.g., Bat-RNP and pPol1-
Bat-NS-Luc) was set at 100%, and the activities with the other two
reporters (e.g., pPol1-FluA-NS-Luc and pPol1-FluB-NS-Luc) were
presented relative to that (Fig. S3).
The PB2, PB1, PA, and NP compatibility between Bat09 and
the following influenza viruses was examined in the study (Fig. 8):
A/PR/8/1934 (lab adapted human H1N1), A/Ann Arbor/6/
1960 (human H2N2), A/New York/238/2005 (human H3N2);
A/New York/1692/2009 (human H1N1 seasonal), A/New York/
1682/2009 (human H1N1 pandemic), A/canine/New York/
6977983/2010 (canine H3N8), A/turkey/Ontario/7732/1966
(avian H5N9), A/Hong Kong/213/2003 (avian H5N1), A/
Anhui/1/2013 (human H7N9), B/Russia/1969 (lab adapted
human IBV), and A/flat-faced bat/Peru/033/2010 (bat
H18N11). For the compatibility test between Bat09 and IAVs
(Fig. 8A–I), 293T cells were co-transfected with 0.2 mg each of
the PB2, PB1, PA, NP (from Bat09 or IAV), 0.1 mg of pPolI-Bat-
NS-Luc plasmid and 0.1 mg of pPolI-FluA-NS-Luc. For compat-
ibility test between Bat09 and IBV (Fig. 8J), 293T cells were co-
transfected with 0.2 mg each of the PB2, PB1, PA, NP (from Bat09
or B/Russia/1969), 0.1 mg of pPolI-Bat-NS-Luc plasmid and
0.1 mg of pPolI-FluB-NS-Luc. For compatibility test between
Bat09 and Bat10 (Fig. 8K), 0.2 mg each of the PB2, PB1, PA, NP
(from Bat09 or Bat10), and pPolI-Bat-NS-Luc plasmids were used
(The NS non-coding regions of Bat09 and Bat10 have the same
sequence). Renilla luciferase was also co-transfected and dual-
luciferase reporter assay system was used. For each combination of
PB2, PB1, PA, and NP (from Bat09 or another influenza virus),
three independent replicates were conducted at 37uC, the
luciferase activity of the all-Bat09-combination (Bat09-PB2/
Bat09-PB1/Bat09-PA/Bat09-NP) was set at 100%, and the
activities of other 15 combinations were presented relative to that.
Pathogenicity of PR8, modified bat-influenza virus
(Bat09:mH1mN1) and PB2 mutants
A total of 98 female BALB/c mice aged 6 to 7 weeks were
randomly allocated to 7 groups (14 mice/group). Six mice were
intranasally inoculated with 103 TCID50 of each virus (Bat
09:mH1mN1, Bat09:mH1mN1-PB2-701D, Bat09:mH1mN1-PB2-
627K701D, Bat09:mH1mN1-PB2-158G701D, Bat09:mH1mN1-
PB2-158G, PR8, or MEM Mock) in 50 mL fresh MEM medium
while under light anesthesia by inhalation of 4% isoflurane. To
determine the virus replication in mouse lungs, three mice from
each group were euthanized on both 3 and 5 day post-
inoculation (dpi). Another 8 mice from each group were
intranasally inoculated with 104 TCID50 of viruses in 50 mL
MEM medium; all eight mice were kept to monitor body
weights and clinical signs. Weights were recorded daily and
general health status was observed twice daily. After the onset of
disease, the general health status was observed three times daily.
Severely affected mice (i.e., more than 25% body weight loss)
were euthanized immediately, and the remaining mice were
euthanized on 14 dpi. All control mice were intranasally
inoculated with 50 mL fresh MEM (mock group), three control
mice were necropsied at 3 and 5 dpi, the remaining mice were
kept until the end of the animal study.
During necropsy, the right part of the lung was frozen at 280uC
for virus titration, and the left part of the lung was fixed in 10%
formalin for histopathologic examination. For virus titration, the
10% lung homogenate was prepared in cold fresh MEM medium
by using a Mini Bead Beater-8 (Biospec Products; 16 Bartlesville,
OK). The homogenate was centrifuged at 6000 rpm for 5 min-
utes, and the supernatant was titrated by infecting MDCK cells in
96-well plates. For the histopathologic examination, lung tissues
fixed in 10% phosphate-buffered formalin were processed
routinely and stained with hematoxylin and eosin. The lungs
were examined microscopically both for the percentage of the lung
involved and for the histopathologic changes seen, including
bronchiolar and alveolar epithelial necrosis, intraalveolar neutro-
philic inflammation, peribronchiolar inflammation, and bronchi-
olar epithelial hyperplasia and atypia. For detection of virus NP
antigens in lung sections on day 5 post infection, a rabbit anti-
H1N1 (2009 flu pandemic) NP polyclonal antibody was used
(Genscript, USA). A pathologist examined each slide in a blinded
fashion.
Pathogenicity of modified bat-influenza viruses
(Bat09:mH1mN1ss) containing truncated NS1 genes
A total of 70 female BALB/c mice aged 6 to 7 weeks were
randomly allocated to 5 groups (14 mice/group). To determine
virus replication, six mice were intranasally inoculated with
104 TCID50 of each virus (Bat09:mH1mN1ss-NS1-WT,
Bat09:mH1N1ss-NS1-73, Bat09:mH1mN1ss-NS1-128, and PR8-
NS1-126) in 50 mL MEM medium while under light anesthesia by
inhalation of 4% isoflurane. Three mice from each group were
killed on both 3 and 5 day post-inoculation (dpi). Another 8 mice
from each group were intranasally inoculated with 105 TCID50 of
each virus in 50 mL MEM medium for morbidity and mortality
comparison. All the other procedures are same with described
previously.
Pathogenicity of TX98 and modified bat influenza
(Bat09:mH3mN2) viruses
A total of 42 female BALB/c mice aged 6 to 7 weeks were
randomly allocated to 3 groups (14 mice/group). To investigate
virus replication in mice, six mice from each group were
intranasally inoculated with 36104 TCID50 of virus or mock-
inoculated with 50 mL fresh MEM medium while under light
anesthesia by inhalation of 4% isoflurane. Three of six inoculated
mice from each group were euthanized at 3 and 5 day post-
inoculation (dpi). To evaluate viral pathogenicity in mice, the
remaining eight mice from each group were intranasally
inoculated with 36105 TCID50 of virus (Bat09:mH3mN2, and
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TX98) in 50 mL fresh MEM medium or mock-inoculated with
50 mL fresh MEM medium. The mice were monitored body
weights and general health status daily. After the onset of disease,
the general health status was observed twice per day. Severely
affected mice (i.e., more than 25% body weight loss) were humanly
euthanized, and the remaining mice were euthanized and bloods
were collected from each mouse to isolate serum for the HI assay
at 14 dpi. Sample collection and analysis, and virus titration were
performed as described above.
Co-infection study for assessment of reassortment
To study the reassortment between Bat09:mH1mN1 and PR8
or Bat10:mH1mN1, confluent monolayer of MDCK cells in
6-well-plates were co-infected with both viruses (Bat09:mH1mN1
and PR8, or Bat09:mH1mN1 and Bat10:mH1mN1). Both
modified Bat09:mH1mN1 and Bat10:mH1mN1 viruses showed
similar replication kinetics in MDCK cells, whereas the PR8
replicated more efficiently than both modified viruses in MDCK
cells. Therefore, for the co-infection study with PR8 and
Bat09:mH1mN1 viruses, the cells were infected with the PR8 at
MOI of 1 and with the Bat09:mH1mN1 at MOI of 4 (a ratio of
both viruses is 1:4). For the co-infection study with
Bat09:mH1mN1 and Bat10:mH1mN1 viruses, the cells were
infected with each virus at MOI of 1 (a ratio of both viruses is 1:1).
The co-infected MDCK cells were incubated at 37uC with 5%
CO2 for 1 hour. After 1 hour of incubation, the supernatant
was removed and the infected cells were washed with fresh MEM
for 10 times. One mL of infection medium supplemented with
1 mg/mL TPCK-trypsin (Worthington, Lakewood, NJ) was added
on cells. The supernatant containing progeny viruses was collected
at 24 hours after inoculation. Plaque assays were performed in
MDCK cells to select single virus from co-infected supernatants.
The purified single virus (plaque) was amplified for further
analysis. To identify the origin of each gene of the purified single
virus, specific RT-PCR was used to differentiate internal genes
from Bat09:mH1mN1, Bat10:mH1mN1 and PR8 viruses (primers
for specific RT-PCR are available upon request). The surface HA
and NA genes were differentiated by sequencing HA and NA non-
coding regions (packaging signals) since three parental viruses
contain identical HA and NA ORF sequences and different
sequences in non-coding region (it is difficult to differentiate them
by RT-PCR). For the RT-PCR, RNAs were extracted from each
amplified single virus using a QIAamp Viral RNA Mini Kit
(Qiagen). cDNA was synthesized by using the bat universal 12
primer (59-AGCAGAAGCAGG-39) for the samples from the co-
infection study with Bat09:mH1mN1 and Bat10:mH1mN1
viruses, and by using a mixture of an IAV universal 12 primer
(59-AGCRAAAGCAGG-39) and the bat universal 12 primer (59-
AGCAGAAGCAGG-39) for the samples from the co-infection
study with Bat09:mH1mN1 and PR8 viruses. If the origin of
internal genes determined by the specific RT-PCR was inconclu-
sive, sequencing was performed to confirm the results from specific
RT-PCR (All sequence primers are available upon request).
Statistical analysis
Luciferase activity, virus titers, and mouse weights were
analyzed by using analysis of variance (ANOVA) in GraphPad
Prism version 5.0 (GraphPad software Inc, CA). One-way
ANOVA with Dunnett’s multiple comparison test was used to
determine the significance of the differences (P,0.05) among
different groups. For simple comparisons, Student’s t test was used
to examine the significance of differences observed. Error bars
represent standard deviation (6SD).
Supporting Information
Figure S1 Synthetic generation of the eight full-length
genomic segments of A/little yellow-shouldered bat/
Guatemala/164/2009 (Bat09). The products were assembled
from oligonucleotides and error corrected. L: 1 Kb Plus DNA
ladder from Life Technologies.
(TIF)
Figure S2 Diagrams of select constructs and viruses
used in this study. All constructs shown are in cDNA sense
complementary to viral RNA. (A) Modified HA (mH1) and
modified NA (mN1). To construct the mH1, PR8-HA coding
region was flanked by the putative packaging regions from Bat09-
HA and all ATG in the Bat09-HA 59 packaging region were
mutated. To construct the mN1, PR8-NA coding region was
flanked by the putative packaging regions from Bat09-NA and all
ATG in the Bat09-NA 59 packaging region were mutated. Batps-
B/NA was constructed similarly with the packaging regions from
Bat09-NA and the coding region from B/Russia/1969-NA. (B)
mH1ss was constructed by introducing 64 of silent substitutions
into the coding region of mH1 to disrupt the remaining packaging
signals in the PR8-HA coding region. mN1ss was constructed by
introducing 90 of silent substitutions into the coding region of
mN1 to disrupt the remaining packaging signals in the PR8-NA
coding region. The mH1ss was referred as H17ps-H1ss and the
mN1ss was referred as N10ps-N1ss in Table 5. The H18ps-H1ss
and N11ps-N1ss have the HA and NA packaging regions from
Bat10. (C) The wild type NS gene and the NS1 truncated NS gene
from Bat09. NS1 truncated PR8-NS genes were constructed
similarly. (D) Bat09 NP and NS coding regions flanked by putative
cis-acting packaging regions from PR8 NP and NS. PR8 NP and
NS coding regions flanked by putative cis-acting packaging regions
from Bat NP and NS. (E) The pPol1-Bat-NS-Luc, pPol1-FluA-NS-
Luc, and pPol1-FluB-NS-Luc reporter genes.
(TIF)
Figure S3 Compatibility between RNPs and viral RNA
promoters from different viruses. Left, RNP from Bat09
and luciferase reporter flanked by NS non-coding regions from
bat-influenza virus, IAV, and IBV. Middle, RNP from influenza A
and the three luciferase reporters. Right, RNP from IBV and the
three luciferase reporters. Within each group of RNP, * indicates
P,0.05, compared to the vRNA reporter from the same type of
virus as the RNP.
(TIF)
Figure S4 Sequence alignment of PR8-HA, mH1, mH1ss
and PR8-NA, mN1, mN1ss.
(TIF)
Table S1 Rescue result of reassortment between Bat09
and PR8.
(TIF)
Table S2 Co-infection results for reassortment between
Bat09:mH1mN1 and Bat10:mH1mN1.
(TIF)
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